ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0490

Fine Specificity Anti-Citrullinated Protein Antibodies as Biomarkers for Prediction of Incident Rheumatoid Arthritis-Associated Interstitial Lung Disease

Vanessa Kronzer1, Weixing Huang2, Paul Dellaripa3, Sicong Huang4, Vivi Feathers2, Bing Lu5, Christine Iannaccone4, Ritu Gill6, Hiroto Hatabu7, Mizuki Nishino7, Cynthia Crowson8, John Davis1, William Robinson9, Tripta Rughwani9, Jeremy Sokolove10, Michael Weinblatt4, Nancy Shadick11, Tracy J. Doyle12 and Jeffrey Sparks11, 1Mayo Clinic, Rochester, MN, 2Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, 3Division of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts, USA, Boston, MA, 4Brigham and Women's Hospital, Boston, MA, 5Brigham and Women's Hospital and Harvard Medical School, Newton, MA, 6Beth Israel Deaconess Medical Center, Boston, MA, 7Department of Radiology; Brigham and Women’s Hospital, Boston, 8Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, 9Stanford University, Palo Alto, CA, 10Stanford University, Mountain View, CA, 11Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 12Brigham and Women's Hospital, West Roxbury, MA

Meeting: ACR Convergence 2020

Keywords: Anti-citrullinated Protein Autoantibodies (ACPAs), Biomarkers, interstitial lung disease, prognostic factors, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: RA – Diagnosis, Manifestations, & Outcomes III: Major Comorbidities in RA (0489–0493)

Session Type: Abstract Session

Session Time: 5:00PM-5:50PM

Background/Purpose: Seropositivity for anti-citrullinated protein antibodies (ACPA) has been shown to increase risk for RA-associated interstitial lung disease (RA-ILD). However, RA-related autoantibodies used in clinical care are unable to accurately predict future RA-ILD. Previous investigations of specific ACPA and RA-ILD were cross-sectional and had inconsistent results. Therefore, we aimed to investigate fine specificity ACPA and subsequent risk of RA-ILD.

Methods: We performed a nested case-control study among patients with RA in a single center prospective registry. Three radiologists/pulmonologists confirmed RA-ILD through research review of the images of chest computed tomography imaging (index date). We matched each incident RA-ILD case to three RA controls (without patient/physician report or billing codes for ILD) on age, sex, RA duration, rheumatoid factor (RF) status, and time from blood draw to index date. Reactivities to three isotypes of 26 different fine specificity ACPA were measured from serum using a previously developed multiplex bead-based platform. The primary analysis investigated log-transformed levels of IgG ACPA. Secondary analyses considered IgA1 and IgA2 isotypes. Covariates at time of blood draw included smoking pack-years, BMI, and RA clinical factors. Conditional logistic regression estimated ORs for RA-ILD, adjusting for matching factors and covariates. We accounted for multiple comparisons using a 10% false discovery rate.

Results: We identified 84 incident RA-ILD cases and 243 RA controls without ILD. Mean age was 65.8 years, 79.2% were female, 89.0% were seropositive for ACPA/RF, and median RA duration was 19 years. Blood was drawn a median of 1.7 years prior to the index date of RA-ILD. After accounting for multiple comparisons, four IgG ACPA biomarkers were significantly associated with subsequent risk of RA-ILD (Table 1). Filaggrin_48_65_cit2_cyclic was strongly associated with increased risk for incident RA-ILD (multivariable OR 3.08 per each log-transformed unit, 95%CI 1.63-5.84) adjusted for matching factors, smoking pack-years, and BMI. Clusterin_231_250_cit_cyclic (OR 1.24, 95%CI 1.04-1.48), fibronectin_cit_1035_1036 (OR 1.20, 95%CI 1.02-1.42), and H4_33_48_cit39_40 (OR 1.23, 95%CI 1.04-1.46) were also associated with incident RA-ILD. The association of filaggrin_48_65_cit2_cyclic with RA-ILD was also observed in the IgA1 (OR 1.83, 95%CI 1.03-3.26) and IgA2 (OR 4.36, 95%CI 1.13-16.90) isotype analyses.

Conclusion: We identified several fine specificity ACPA associated with subsequent risk of RA-ILD that may inform pathogenesis. In particular, autoimmunity to a specific citrullinated epitope of filaggrin was associated with RA-ILD across all isotypes investigated and is potentially a novel predictive biomarker for RA-ILD. External replication is in process, but these results suggest that fine specificity ACPA biomarkers may have utility in RA-ILD prediction.

Table 1. Associations of log-transformed IgG fine specificity ACPA with incident RA-ILD in 84 RA-ILD cases and 243 RA controls without ILD.


Disclosure: V. Kronzer, None; W. Huang, None; P. Dellaripa, Genentech, 1, Bristol Myers Squibb, 1; S. Huang, None; V. Feathers, None; B. Lu, None; C. Iannaccone, None; R. Gill, None; H. Hatabu, None; M. Nishino, Merck, 1, Daiichi Sankyo, 1, 2, AstraZeneca, 1, 2, Canon Medical Systems grants, 1, Roche, 1; C. Crowson, Myriad Genetics, 1, Pfizer, 1; J. Davis, Pfizer, 2, AbbVie, 5, 8, Sanofi-Genzyme, 5, 8; W. Robinson, None; T. Rughwani, None; J. Sokolove, GlaxoSmithKline, 1; M. Weinblatt, Crescendo Bioscience, 1, Bristol Myers Squibb, 1, Sanofi, 2, Lilly, 1, Amgen, 1, AbbVie, 5, Amgen, 2, 5, Arena, 5, Bristol Myers Squibb, 2, 5, Canfite, 1, 5, Corrona, 5, Crescendo, 2, 5, GlaxoSmithKline, 5, Gilead, 9, Horizon, 9, Johnson and Johnson, 9, Lilly, 2, 9, Pfizer, 9, Scipher, 1, 9, Set Point, 9, Roche, 9, Canfite, 1, Inmedix, 1, Lycera, 1, Vorso, 1, Scipher, 1; N. Shadick, Sanofi, 2, Crescendo Biosciences, 2, Lilly, 2, Bristol-Myers Squibb Company, 2, 5, Amgen, 2, Mallinckrodt, 2; T. Doyle, None; J. Sparks, Optum, 1, Janssen, 1, Inova, 1, Gilead, 1, Amgen, 1, Bristol-Myers Squibb, 1, 2.

To cite this abstract in AMA style:

Kronzer V, Huang W, Dellaripa P, Huang S, Feathers V, Lu B, Iannaccone C, Gill R, Hatabu H, Nishino M, Crowson C, Davis J, Robinson W, Rughwani T, Sokolove J, Weinblatt M, Shadick N, Doyle T, Sparks J. Fine Specificity Anti-Citrullinated Protein Antibodies as Biomarkers for Prediction of Incident Rheumatoid Arthritis-Associated Interstitial Lung Disease [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/fine-specificity-anti-citrullinated-protein-antibodies-as-biomarkers-for-prediction-of-incident-rheumatoid-arthritis-associated-interstitial-lung-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/fine-specificity-anti-citrullinated-protein-antibodies-as-biomarkers-for-prediction-of-incident-rheumatoid-arthritis-associated-interstitial-lung-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology